Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes

Progress in Cardiovascular Diseases

Volumn 44, Issue 3, 2001, Pages 195-206

  Chew, Derek P ^a   Roffi, Marco ^a   Topol, Eric J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Desk F25 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; TIROFIBAN;

COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE MARKER; DRUG EFFICACY; ELECTROCARDIOGRAM; HEART MUSCLE ISCHEMIA; KIDNEY DISEASE; PRACTICE GUIDELINE; REVIEW; SEX DIFFERENCE; ST SEGMENT; STATISTICAL ANALYSIS;

EID: 0035212230     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2001.29143     Document Type: Article

References (59)

1. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network
2. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
3. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
4. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
5. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Unstable Angina)
6. Glycoprotein IIb/IIIa receptor blocker abciximab does not improve outcome in patients with acute coronary syndromes without early revascularization: The GUSTO IV-ACS study
7. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
8. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy
9. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
10. Platelet GPIIb-IIIa blockers
11. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
12. Inside-out integrin signalling
13. Platelet integrins
14. Peptide ligands can bind to distinct sites in integrin alphaIIbbeta 3 and elicit different functional responses
15. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa)
16. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
17. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome. An OPUS-TIMI 16 substudy
18. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials
19. Inflammation and thrombosis: The clot thickens
20. P-selection expression on platelets determines size and stability of platelet aggregates
21. Raised mortality at inflammatory activity or myocardial damage in unstable CAD is reduced by an invasive strategy
22. An elevated white blood cell cound is an independent predictor of mortality in patients with acute coronary syndromes
23. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
24. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
25. Networking in the hemostatic system. Integrin alphaiibbeta 3 binds prothrombin and influences its activation
26. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity
27. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes
28. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
29. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors
30. A prospective multicentre study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary interventin-the GOLD study
31. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion
32. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
33. Tirofiban: A review of its use in acute coronary syndromes
34. Clinical pharmacology of eptifibatide
35. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?
36. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
37. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial
38. Randomised placebocontrolled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
39. Glycoprotein IIb/IIIa inhibitors in the medical management of unstable ischemic syndromes without persistent ST-segment elevation: A meta-analysis of the randomized trials
40. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
41. Results of the treat angina with aggrastat and determine the cost of therapy with an invasive or conservative strategy (TACTICS-TIMI 18) trial: A comparison of invasive versus conservative strategy in patients with unstable angina and non-ST-segment elevation myocardial infarction
42. Invasive compared with noninvasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
43. Plasma concentration of lamifiban and glycoprodtein IIb/IIIa receptor occupancy best predict clinical outcome in patients with unstable angina. Results from PARAGON A
44. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in preventing ischemic complications
45. Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: Applications to highly cited trials in cardiovascular medicine
46. Gender differences in platelet GPIIb-IIIa activation
47. Sex and age differences in human platelet aggregation
48. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9,461 patients
49. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes
50. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus
51. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
52. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy
53. Risks associated with renal dysfunction in patients in the coronary care unit
54. Bleeding and thrombosis in chronic uremia
55. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
56. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet receptor inhibition in ischemic syndrome management
57. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
58. Costeffectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
59. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting